Generic Abuse-Deterrent Opioids: Comparison To Brand Will Not Require Use Of Control
FDA final guidance recommends comparative pharmacodynamic studies for nasal and oral routes of abuse, simplifies statistical approach to show deterrence of generic is same as brand.
You may also be interested in...
Despite ‘tension’ between two industries over what is required to show generic is no less abuse-deterrent than innovator opioid, FDA’s Throckmorton suggests they come up with single approach to product development.
FDA's draft guidance could make it difficult for generics to show abuse deterrence, especially given 'moving target' of innovator labeling changes, generic firms say.
Draft guidance provides roadmap for testing generic solid oral opioid products; FDA's Califf notes difficulty in conducting post-market studies.